DEF: Horizon Space II Seeks Extension for SL Bio Merger

Horizon Space Acquisition II Corp. (HSPT) is seeking shareholder approval to extend its business combination deadline to February 2027 to complete its proposed merger with SL Bio Ltd. or an alternative.

Summary

• HSPT is holding an Extraordinary General Meeting on February 13, 2026, to vote on proposals to extend its deadline to complete a business combination.
• The current deadline for completing a business combination is February 18, 2026, with a possible extension to May 18, 2026, under existing terms.
• The proposed amendments (MAA Amendment Proposal and Trust Amendment Proposal) would allow HSPT to extend the deadline monthly, up to twelve times, until February 18, 2027, without requiring further shareholder approval for each monthly extension.
• Each monthly extension requires the Sponsor and/or its designee to deposit the lesser of $50,000 for all remaining public shares or $0.033 for each remaining public share into the Trust Account.
• HSPT entered into a Business Combination Agreement with SL Science Holding Limited (PubCo) and SL BIO Ltd. (SL Bio) on May 9, 2025, which is subject to shareholder approval at a separate meeting on February 12, 2026, and Nasdaq listing approval.
• If the extension proposals are not approved, and a business combination is not completed by February 18, 2026 (or May 18, 2026, if extended), HSPT will cease operations, redeem public shares at approximately $10.53 per share (as of December 29, 2025), and liquidate.
• Public shareholders have redemption rights, allowing them to redeem their shares for cash from the Trust Account, regardless of how they vote on the extension proposals. The redemption price as of December 29, 2025, was approximately $10.53 per public share, while the Nasdaq closing price was $10.55.
• The extension proposals require a special resolution (two-thirds affirmative vote) under Cayman Islands law. The Adjournment Proposal requires an ordinary resolution (majority vote).
• The Sponsor and Insiders, collectively owning approximately 21.35% of outstanding Ordinary Shares, plan to vote in favor of the extension proposals.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development. While the extension provides more time, it highlights the ongoing challenges in closing the SL Bio transaction and introduces new risks related to potential redemptions and regulatory complexities, particularly concerning China and investment company status.

Positives

• Provides HSPT with more time and flexibility (up to an additional 12 months, until February 18, 2027) to complete its initial business combination, either with SL Bio or an alternative target.
• The Sponsor and/or its designee will deposit monthly extension fees into the Trust Account, benefiting non-redeeming public shareholders by increasing the per-share redemption value over time (estimated $10.62 by February 18, 2027, if fully extended).
• Public shareholders retain redemption rights, offering a cash exit option at a price close to the current market value, regardless of their vote on the extension.
• The Board unanimously recommends approval, believing it is in the best interests of the Company and its shareholders.

Negatives

• Uncertainty regarding the completion of the SL Bio Transactions or any alternative business combination, even with the extension.
• Potential for significant redemptions by public shareholders, which could leave HSPT with insufficient cash to consummate a business combination on commercially acceptable terms.
• The redemption price ($10.53 as of December 29, 2025) is slightly lower than the market price ($10.55), meaning shareholders exercising redemption would receive $0.02 less per share than selling in the open market.
• Additional expenses will be incurred by the Company in seeking to complete a business combination, including extension fees.
• Risk of being deemed an unregistered investment company under new SEC SPAC Final Rules, which could force liquidation and cause rights to expire worthless.
• Insiders have conflicts of interest, as their founder shares and private units would become worthless if a business combination is not completed, incentivizing them to complete a deal even if less favorable to public shareholders.
• Significant ties to China (CEO/CFO, Sponsor director located in China) may make HSPT a less attractive partner for non-China-based targets and could subject a PRC target company to complex and uncertain Chinese regulatory approvals (CSRC, CAC), potentially hindering or delaying a business combination.
• Enforcement risks for civil liabilities due to executive officers and directors being located outside the United States (China, Singapore).
• Potential impact of U.S. foreign investment regulations (CFIUS) if a U.S. business in a sensitive industry is targeted, which could block or delay a transaction.

Risks

• Inability to obtain approval for the Extension Proposals or the Adjournment Proposal.
• Inability to complete the initial business combination (SL Bio Transactions or an alternative) even if extensions are approved.
• High amount of redemptions by public shareholders, leading to insufficient cash for a business combination.
• Volatility and illiquidity of public securities, making it difficult for shareholders to sell shares at favorable prices.
• Risk of being deemed an investment company under the Investment Company Act, potentially forcing liquidation and causing rights to expire worthless.
• The Trust Account being subject to claims of third parties.
• Uncertainty of interpretation and application of PRC laws and regulations if a PRC Target Company is acquired, including potential requirements for approval from Chinese authorities (CSRC, CAC) for listing on U.S. exchanges or issuing securities.
• Enforcement risks related to civil liabilities due to executive officers and directors being located outside the United States (China, Singapore).
• Potential restrictions or delays due to U.S. foreign investment regulations (CFIUS) if a U.S. business is targeted, especially in sensitive industries.
• Onerous and time-consuming documentation requirements under the HFCAA if a foreign public accounting firm not subject to PCAOB inspection is used.
• Insiders' interests may conflict with those of other shareholders, as they are incentivized to complete a business combination to avoid their investments becoming worthless.

Future Outlook

The company aims to complete its initial business combination, specifically the SL Bio Transactions, or an alternative, by the extended deadline of February 18, 2027, if the extension proposals are approved. Management believes these extensions provide necessary time and flexibility. However, there is no assurance that a business combination will be consummated, or that sufficient cash will remain after redemptions. The company may also face liquidation if a business combination is not completed within the prescribed timeline.

Management Comments

• The Board is not certain whether there will be sufficient time before February 18, 2026 for the Company to complete the SL Bio Transactions and has determined that it is in the interests of our shareholders to approve the Extension Proposals in order to adopt the MAA Amendment and the Trust Agreement.
• After careful consideration of all relevant factors, the Board has determined that the MAA Amendment Proposal, the Trust Amendment Proposal, and, if presented, the Adjournment Proposal, are advisable and in the best interests of the Company, and recommends that you vote or give instruction to vote FOR each of the MAA Amendment Proposal, the Trust Amendment Proposal, and, if presented, the Adjournment Proposal.
• Our Board believes shareholders will benefit from the Company consummating a business combination and is proposing the MAA Amendment Proposal and the Trust Amendment Proposal to allow us more time and flexibility to complete the initial business combination.
• The Board determined that their respective personal pecuniary interests, in the form of the contingent and hypothetical value of Company shares if a business combination is ultimately completed, was substantially less than the additional time, effort and potential liability they might incur if they failed to discharge their fiduciary duties to the Companys shareholders to the best of their ability, which they, as Company shareholders as well, share.

Industry Context

StockSavvy.ai notes that this filing is typical for a Special Purpose Acquisition Company (SPAC) nearing its initial business combination deadline. The request for an extension reflects the common challenges SPACs face in identifying and closing suitable mergers within their initial timeframe, especially given the current regulatory scrutiny on SPACs (e.g., SEC's SPAC Final Rules regarding investment company status). The proposed monthly extension mechanism, funded by the sponsor, is a common strategy to buy more time while minimizing immediate dilution or large upfront costs compared to a single, longer extension. The mention of potential CFIUS review and PRC regulatory hurdles highlights the increasing complexity and geopolitical risks associated with cross-border SPAC transactions, particularly those involving entities with significant ties to China.

Comparison to Industry Standards

• The proposed extension mechanism, where the sponsor contributes monthly fees to the trust account, is a standard practice in the SPAC industry to incentivize public shareholders to remain invested while the SPAC seeks to complete a business combination.
• The redemption price of approximately $10.53 per share, compared to the IPO price of $10.00, indicates a modest return for redeeming shareholders, which is typical for SPACs that have held funds in a trust account earning interest.
• The requirement for a two-thirds shareholder vote for charter amendments is standard for significant corporate governance changes in Cayman Islands incorporated companies.
• The disclosure of potential risks related to being deemed an investment company under the SEC's SPAC Final Rules (effective July 1, 2024) is a new and critical consideration for all SPACs, reflecting heightened regulatory oversight.
• The explicit mention of risks related to PRC authorities (CSRC, CAC) and U.S. foreign investment regulations (CFIUS) is increasingly common for SPACs with management or target companies tied to China, distinguishing them from SPACs focused purely on domestic U.S. targets. For example, other SPACs like 'XYZ SPAC' targeting a U.S. tech company might not face these specific geopolitical and regulatory risks.

Corporate Governance

Related Party Transactions

• The Sponsor and/or its designee will deposit monthly extension fees into the Trust Account, specifically the lesser of $50,000 for all remaining public shares or $0.033 for each remaining public share, for up to twelve months.
• The Sponsor, affiliates of the Sponsor, HSPT's directors and officers may loan HSPT funds as required to finance transaction costs in connection with an intended initial business combination.
• Insiders, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred related to identifying, investigating, and consummating an initial business combination.
• The Sponsor has the right, but not the obligation, to convert promissory notes (including the $690,000 note issued on November 18, 2025) into PubCo ordinary shares upon the consummation of the business combination.
• Mingyu (Michael) Li, the Company's Chief Executive Officer, Chief Financial Officer, and Chairman, is the sole director of the Sponsor and is deemed to have sole voting and investment discretion over the securities held by the Sponsor.

Stakeholder Impact

• Shareholders: Public shareholders who redeem will receive cash at approximately $10.53 per share (as of December 29, 2025), slightly below the market price. Those who do not redeem face extended investment duration with potential for increased value if a successful business combination occurs, but also risk of liquidation if no deal is found. They will benefit from monthly extension fees deposited into the Trust Account by the Sponsor.
• Insiders (Sponsor, officers, directors): Benefit significantly if a business combination is completed, as their founder shares and private units would otherwise become worthless. Their interests may conflict with public shareholders.
• Creditors: The Trust Account funds are protected for public shareholders. Other assets outside the Trust Account would be used to pay creditors in case of liquidation. The $690,000 promissory note to Hsiao-Lan Wu is an unsecured debt.

Next Steps

• Extraordinary General Meeting on February 13, 2026, to vote on Extension Proposals.
• Business Combination Meeting on February 12, 2026, to vote on SL Bio Transactions.
• If Extension Proposals are approved, file amendments to MAA and Trust Agreement with Registrar of Companies in Cayman Islands.
• If Extension Proposals are approved, Sponsor/designee to deposit monthly extension fees into Trust Account by the 18th of each succeeding month until February 18, 2027.
• Continue efforts to consummate the SL Bio Transactions or an alternative business combination by the extended deadline of February 18, 2027.
• If Extension Proposals are not approved and no business combination by February 18, 2026 (or May 18, 2026, if extended), the company will cease operations, redeem public shares, and liquidate.
• Publish final voting results in a Current Report on Form 8-K within four business days following the Extraordinary Meeting.

Key Dates

Recommendation

The filing presents a mixed bag. While the extension provides a necessary lifeline for the SPAC to complete its proposed merger with SL Bio or find an alternative, it also highlights the ongoing challenges and introduces new risks, particularly around potential redemptions and regulatory hurdles. The slight discount of the redemption price to the market price suggests that immediate redemption is not optimal. Given the uncertainty of the business combination and the inherent risks of SPACs, a 'hold' recommendation is appropriate for existing shareholders to await further developments, especially the outcome of the business combination vote, while new investors should exercise caution due to the elevated risk profile.

Keywords

SPAC, Business Combination, Extension Proposal, Proxy Statement, SEC Filing, Horizon Space Acquisition II Corp, HSPT, SL Bio, Merger, Redemption Rights, Trust Account, Corporate Governance, Cayman Islands, Investment Company Act, CFIUS, China Risks, Nasdaq